2024
Trends and predictors of Quality of Life in lung cancer survivors
Bade B, Zhao J, Li F, Tanoue L, Lazowski H, Alfano C, Silvestri G, Irwin M. Trends and predictors of Quality of Life in lung cancer survivors. Lung Cancer 2024, 191: 107793. PMID: 38640687, DOI: 10.1016/j.lungcan.2024.107793.Peer-Reviewed Original ResearchConceptsFunctional Assessment of Cancer Therapy - LungNon-small cell lung cancerHR-QOL scoresLung cancer survivorsHR-QOLAdvanced stage non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerQuality of lifeCancer survivorsPhysical activityCell lung cancerEarly-stage diseasePredictors of quality of lifeHealth-related quality of lifeFollow-upHealth-related qualityHealthy weight maintenancePerformance statusAdvanced-stage non-small cell lung cancerLung cancerClinical significanceAssociated with older ageDiagnosed NSCLCTreatment-related side effects
2021
“Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”
Bade BC, Gan G, Li F, Lu L, Tanoue L, Silvestri GA, Irwin ML. “Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”. BMC Cancer 2021, 21: 352. PMID: 33794808, PMCID: PMC8015735, DOI: 10.1186/s12885-021-08084-0.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced-stage lung cancerStage lung cancerUsual carePhysical activityIntervention groupQuality of lifeLung cancerEligible patientsStage III/IV non-small cell lung cancerLow baseline physical activityHome-based physical activityAdvanced stage diseaseSoluble PD-1Stage IV adenocarcinomaBaseline physical activityMinority of patientsCell lung cancerPatient-reported outcomesEffects of exerciseRole functioning domainsLung cancer biologyAspects of QoL.Mobile health interventionsCancer biomarkers
2018
Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose
Ye Q, Wu J, Lu Y, Naganawa M, Gallezot JD, Ma T, Liu Y, Tanoue L, Detterbeck F, Blasberg J, Chen MK, Casey M, Carson RE, Liu C. Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose. Physics In Medicine And Biology 2018, 63: 175015. PMID: 30095083, PMCID: PMC6158045, DOI: 10.1088/1361-6560/aad97f.Peer-Reviewed Original ResearchConceptsPopulation-based input functionStandardized uptake valueImage-derived input functionLung nodulesClinical trialsTime-activity curvesLow-dose computed tomography (LDCT) screeningLung cancer mortality ratesIndeterminate lung nodulesComputed Tomography ScreeningF-FDG PETCancer mortality ratesStatic PET acquisitionVirtual clinical trialsScan durationTomography screeningFDG injectionPET scansMortality rateUptake valueAccurate diagnosisMalignant lung nodulesROC analysisPatient dataMalignant nodulesIncorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement
Rivera MP, Tanner NT, Silvestri GA, Detterbeck FC, Tammemägi MC, Young RP, Slatore CG, Caverly TJ, Boyd CM, Braithwaite D, Fathi JT, Gould MK, Iaccarino JM, Malkoski SP, Mazzone PJ, Tanoue LT, Schoenborn NL, Zulueta JJ, Wiener RS. Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement. American Journal Of Respiratory And Critical Care Medicine 2018, 198: e3-e13. PMID: 30004250, DOI: 10.1164/rccm.201805-0986st.Peer-Reviewed Original ResearchConceptsLung cancer screeningRisk of deathPatient selectionChronic illnessCancer screeningLung cancerOfficial American Thoracic Society Research StatementHarms of LCSImplementation of LCSScreen-detected lung cancersChronic obstructive pulmonary diseaseRisk of comorbiditiesObstructive pulmonary diseaseEffect of comorbidityLung cancer deathsTreatment-related harmsLung cancer riskBalance of benefitsPulmonary diseaseCancer deathBaseline riskCancer riskComorbiditiesHealthy individualsInternational clinicians
2016
Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population
Erb CT, Su KW, Soulos PR, Tanoue LT, Gross CP. Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population. Lung Cancer 2016, 99: 200-207. PMID: 27565940, PMCID: PMC5003420, DOI: 10.1016/j.lungcan.2016.07.017.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerCurative-intent therapyCell lung cancerLung cancerPractice patternsMedicare populationEarly-stage non-small cell lung cancerStage non-small cell lung cancerPositron emission tomography scanRoutine imaging surveillanceSpecialty society recommendationsPercent of patientsEmission tomography scanEvidence-based guidelinesRecent practice patternsMore comorbiditiesGuideline adherenceImaging surveillanceProvider factorsSociety guidelinesSurveillance guidelinesSurveillance imagingPrimary carePrimary treatment
2015
Lung Cancer Screening
Tanoue LT, Tanner NT, Gould MK, Silvestri GA. Lung Cancer Screening. American Journal Of Respiratory And Critical Care Medicine 2015, 191: 19-33. PMID: 25369325, DOI: 10.1164/rccm.201410-1777ci.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyLung cancerUnited States Preventive Services Task ForcePack-year smoking historyNational Lung Screening TrialLung cancer screeningUnnecessary invasive testingFalse-positive findingsAspects of screeningLDCT screeningSmoking historyCancer screeningMortality burdenInvasive testingHigh riskScreening TrialComputed tomographyRisk of harmAge 55Positive findingsCancerEffective screeningPossible harmScreeningTask Force
2013
Use of New Treatment Modalities for Non-small Cell Lung Cancer Care in the Medicare Population
Vest MT, Herrin J, Soulos PR, Decker RH, Tanoue L, Michaud G, Kim AW, Detterbeck F, Morgensztern D, Gross CP. Use of New Treatment Modalities for Non-small Cell Lung Cancer Care in the Medicare Population. CHEST Journal 2013, 143: 429-435. PMID: 23187634, PMCID: PMC3566996, DOI: 10.1378/chest.12-1149.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerVideo-assisted thoracoscopic surgeryProportion of patientsOlder patientsCancer careNon-small cell lung cancer careEarly-stage non-small cell lung cancerStage non-small cell lung cancerEnd Results-Medicare databaseLung cancer careCell lung cancerCurative local therapyNew treatment modalitiesOverall useNew surgical techniqueType of treatmentNew radiation modalitiesRadiation therapy modalitiesSurgical resectionCurative therapyLocal therapyMore patientsThoracoscopic surgeryMean age
2012
Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer
Vest MT, Tanoue L, Soulos PR, Kim AW, Detterbeck F, Morgensztern D, Gross CP. Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2012, 7: 188-195. PMID: 22134069, PMCID: PMC3253367, DOI: 10.1097/jto.0b013e318236ecbb.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiopsy, NeedleCarcinoma, Non-Small-Cell LungCohort StudiesComorbidityConfidence IntervalsGuideline AdherenceHumansLung NeoplasmsLymph NodesMediastinoscopyMediastinumMedicareMultivariate AnalysisNeoplasm StagingOdds RatioPositron-Emission TomographySEER ProgramSurvival AnalysisUnited StatesConceptsStage IIIA non-small cell lung cancerIIIA non-small cell lung cancerNon-small cell lung cancerInvasive stagingCell lung cancerMediastinal stagingLung cancerClinical stage IIIA non-small cell lung cancerEnd Results-Medicare databaseStage IIIA NSCLC patientsPositron emission tomography scanningPathologic lymph nodesIIIA NSCLC patientsMultivariable logistic regressionInvasive mediastinal stagingNSCLC patientsOlder patientsPatient characteristicsLymph nodesPatient factorsHistologic confirmationPractice patternsMedicare claimsMedicare beneficiariesPET scanning
2011
Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assay
Anagnostou VK, Dimou AT, Botsis T, Killiam EJ, Gustavson MD, Homer RJ, Boffa D, Zolota V, Dougenis D, Tanoue L, Gettinger SN, Detterbeck FC, Syrigos KN, Bepler G, Rimm DL. Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assay. Cancer 2011, 118: 1607-1618. PMID: 22009766, DOI: 10.1002/cncr.26450.Peer-Reviewed Original Research
2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2009
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL. High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma. Clinical Cancer Research 2009, 15: 4157-4164. PMID: 19509151, DOI: 10.1158/1078-0432.ccr-09-0099.Peer-Reviewed Original ResearchConceptsLung cancer patientsMTOR expressionCancer patientsMammalian targetEarly-stage lung adenocarcinomaHigh mTOR expressionIndependent lower riskMedian overall survivalStage IA patientsProtein expressionSubgroup of patientsLung adenocarcinoma patientsStage lung adenocarcinomaMTOR protein expressionRole of mTOROverall survivalPathologic characteristicsPatient survivalValidation cohortAdenocarcinoma groupAdenocarcinoma patientsPrognostic stratificationLung cancerTraining cohortFavorable outcome
2007
Treatment of Lung Cancer in Older Patients
Tanoue LT, Gettinger S. Treatment of Lung Cancer in Older Patients. Clinics In Chest Medicine 2007, 28: 735-749. PMID: 17967291, DOI: 10.1016/j.ccm.2007.08.003.Peer-Reviewed Original Research
2006
High Rate of Negative Results of Tuberculin and QuantiFERON Tests Among Individuals With a History of Positive Skin Test Results
Friedman LN, Nash ER, Bryant J, Henry S, Shi J, D'Amato J, Khaled GH, Russi MB, O'Connor PG, Edberg SC, Pisani MA, Cain HC, Tanoue L, Weissman DN. High Rate of Negative Results of Tuberculin and QuantiFERON Tests Among Individuals With a History of Positive Skin Test Results. Infection Control And Hospital Epidemiology 2006, 27: 436-441. PMID: 16671022, DOI: 10.1086/503690.Peer-Reviewed Original ResearchConceptsQuantiFERON-TB testTuberculin skin testPrevious tuberculin skin testTST statusInitial tuberculin skin testPositive tuberculin skin testSecond tuberculin skin testPositive skin test resultsExperienced healthcare workersNegative TST resultsTST-negative groupSkin test resultsTST protocolWhole blood assaysNegative resultsPositive resultsTuberculosis exposureImmunocompetent subjectsQuantiFERON testSkin testTST resultsMedical recordsInduration diameterHealthcare workersHigh risk
2005
Case Study Review
Noble PW, Tanoue L, Homer R. Case Study Review. CHEST Journal 2005, 128: 540s-546s. PMID: 16304245, DOI: 10.1378/chest.128.5_suppl_1.540s.Peer-Reviewed Original Research